Hemab Therapeutics Holdings

Company snapshot

Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hemab Therapeutics Holdings. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Hemab Therapeutics Holdings.

1. May 26, 2026 Clinical update

   HMB-001 — Phase 2

2. May 23, 2026 Clinical update

   HMB-001 — Phase 2

3. May 23, 2026 Clinical update

   HMB-002 (Part A) — Phase 2

4. May 23, 2026 Clinical update

   Sutacimig — Phase 2

View all clinical trial activity →

• What is Hemab Therapeutics Holdings?

  Hemab Therapeutics Holdings is a biotech organization headquartered in frederiksberg, DK. It trades on NYSE under ticker COAG. Primary therapeutic focus areas include Glanzmann Thrombasthenia, Von Willebrand Disease (VWD), Congenital Factor VII Deficiency. NovaPharmaNews links 4

• Is Hemab Therapeutics Holdings publicly traded?

  Yes. Hemab Therapeutics Holdings is listed with ticker COAG on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Hemab Therapeutics Holdings develop or market?

  No drug profiles are currently linked to Hemab Therapeutics Holdings. Pipeline programs may still list investigational assets.

• What are the latest developments for Hemab Therapeutics Holdings?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hemab Therapeutics Holdings focus on?

  Hemab Therapeutics Holdings focuses on Glanzmann Thrombasthenia, Von Willebrand Disease (VWD), Congenital Factor VII Deficiency based on our analysis of their pipeline programs and drug development activities.